Fecal DNA Methylation Test for Colorectal Cancer Screening
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04823793 |
|
Recruitment Status :
Recruiting
First Posted : April 1, 2021
Last Update Posted : April 8, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This is an observational, prospective study using fecal DNA methylation test to define the risk of suffering from advanced adenoma or colorectal cancer (CRC) compared to colonoscopy and fecal immunochemical test (FIT).
This study recruits at least 80 participants, including 40 people of healthy controls, 20 people with adenoma, and 20 people with CRC, which were confirmed by colonoscopy. All fecal specimens from participants will be examined by FIT and multi-methylated target gene detection through real-time quantitative methylation-specific PCR (qMSP).
The objective of this study is to evaluate the sensitivity and specificity of multi-methylated target PCR compared with the FIT and confirm the examination results through colonoscopy.
| Condition or disease | Intervention/treatment |
|---|---|
| Colorectal Cancer Colorectal Adenoma | Diagnostic Test: Stool DNA methylation detection |
The incidence rate and the mortality rate of colorectal cancer (CRC) have been steadily increasing worldwide. Early detection of CRC can provide great opportunities to help patients, increasing their 5-year survival rate. Colonoscopy has been considered as the golden standard of CRC screening method, but the invasive procedures cannot be widely adapted by recipients.
Nowadays, the most common CRC screening method is fecal immunochemical test (FIT) which is a cost-effective and non-invasive approach. The sensitivity of FIT for CRC detection is about 80%, but only 20% for adenoma.
The methylation level of candidate genes are determined by qMSP to estimate the risk of colorectal cancer. This study implements fecal DNA methylation test and fecal immunochemical test simultaneously to evaluate whether the fecal DNA methylation test can improve the detection rate of adenoma and CRC.
| Study Type : | Observational |
| Estimated Enrollment : | 80 participants |
| Observational Model: | Case-Control |
| Time Perspective: | Prospective |
| Official Title: | A Fecal DNA Methylation Test for Colorectal Cancer Screening Using Multitarget Real-Time PCR Method-A Observational, Prospective Study |
| Actual Study Start Date : | March 31, 2021 |
| Estimated Primary Completion Date : | March 20, 2023 |
| Estimated Study Completion Date : | March 20, 2023 |
| Group/Cohort | Intervention/treatment |
|---|---|
|
Healthy group : Stool specimens from participants with healthy colon
Stool specimens will be collected from participants before having a colonoscopy. If the participant's colon has a healthy colon without any cancerous lesion, the stool specimen will be included in the healthy group. |
Diagnostic Test: Stool DNA methylation detection
Stool specimens are collected from participants in the outpatient department or the inpatient department. Both FIT and stool DNA real-time PCR are performed simultaneously. To improve the sensitivity and specificity of the colorectal cancer screening, this study enrolls multiple candidate genes to distinguish whether the participant has a high risk of colorectal cancer. |
|
Disease group : Stool specimens from participants with adenoma/colorectal cancer
Stool specimens will be collected from participants before having a colonoscopy. If the participant's colon has precancerous lesion, such as adenoma, the stool specimen will be included in the disease group. Also, specimens from confirmed colorectal cancer patients are included in the disease group. |
Diagnostic Test: Stool DNA methylation detection
Stool specimens are collected from participants in the outpatient department or the inpatient department. Both FIT and stool DNA real-time PCR are performed simultaneously. To improve the sensitivity and specificity of the colorectal cancer screening, this study enrolls multiple candidate genes to distinguish whether the participant has a high risk of colorectal cancer. |
- Sensitivity and specificity of methylation biomarker and FIT for adenoma and colorectal cancer screening [ Time Frame: 6 months ]
In this study, we estimate the sensitivity and specificity of methylation biomarker isolated from participant's stool DNA and perform FIT simultaneously.
The Ct values of candidate genes and GAPDH (reference gene) are determined by real-time PCR. The delta Ct values are calculated by Ct value of candidate gene - Ct value of GAPDH. Furthermore, the cut-off value of each candidate gene was determined based on the Receiver Operating Characteristic curve.
If the value of Fecal immunochemical test is more than 100 ng Hb/ml, the stool is considered as positive with fecal occult blood.
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 40 Years to 79 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Healthy group :
Participants without any cancerous lesion in their colon
Disease group :
Participants with adenoma or colorectal cancer
Inclusion Criteria:
- Participants with age over 40 but under 80, who need to take colonoscopy or diagnostic confirmed colorectal cancer patient.
Exclusion Criteria:
- Participants who are undergoing cancer treatments or have diagnosed with cancer, received cancer treatment in the past.
- Participants who have received any cancer treatments, including chemotherapy and radiotherapy before taking surgery.
- Participants have received any surgery for colorectal cancer in the past.
- Pregnant women or nursing women.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04823793
| Contact: Yi-Chiao Cheng, MD | +886912959022 | ndmcjoe@gmail.com |
| Taiwan | |
| Tri-Service General Hospital, National Defense Medical Center | Recruiting |
| Taipei, Taiwan | |
| Contact: Yi-Chiao Cheng +886912959022 ndmcjoe@gmail.com | |
| Principal Investigator: | Yi-Chiao Cheng, MD | Tri-Service General Hospital |
| Responsible Party: | Yi-Chiao Cheng, Attending surgeon, division of colon and rectal surgery, Tri-Service General Hospital |
| ClinicalTrials.gov Identifier: | NCT04823793 |
| Other Study ID Numbers: |
A202105054 |
| First Posted: | April 1, 2021 Key Record Dates |
| Last Update Posted: | April 8, 2021 |
| Last Verified: | April 2021 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Fecal immunochemical testing Methylation Stool Colonoscopy |
|
Colorectal Neoplasms Adenoma Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms |
Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |